Back to results
US 8,273,765 B2Granted
Bicyclo-pyrazoles and pharmaceutical compositions comprising them
AssigneePfizer Italia S.r.l.
InventorsDaniele Fancelli, Valeria Pittala′, Mario Varasi
Life of this patent
Estimating the term…
Abstract
Bicyclo-pyrazole compounds of formula (I), as herein defined, are useful for treating diseases linked to disregulated protein kinases.
Claims3
A pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier and/or diluent,
- wherein
- R is an optionally substituted group selected from the group consisting of —COR′, —COOR′, —CONHR′, —CONR′R″, —NH—C(═NH)NHR′, —SO2NHR′ and —SO2NR′R″;
- R1 is a hydrogen atom or an optionally substituted group selected from the group consisting of R′, —COR′, —COOR′, —CONHR′, —CONR′R″, —NH—C(═NH)NHR′, —SO2NHR′ and —SO2NR′R″;
- wherein R′ and R″ are the same or different and are, independently, hydrogen or optionally substituted straight or branched C1-C6 alkyl, aryl, or aryl C1-C6 alkyl, wherein when R′ is hydrogen R″ is not hydrogen, wherein when R″ is hydrogen R′ is not hydrogen and wherein when R1 is hydrogen, R′ is not hydrogen;
- Ra, Rb, Rc and Rd are the same or different and are independently selected among hydrogen, or optionally further substituted straight or branched C1-C6 alkyl, aryl, aryl C1-C6 alkyl or —CH2OR′ groups, wherein R′ is as above defined, or Ra and Rb and/or Rc and Rd, taken together with the carbon atom to which they are bonded, form an optionally substituted C3-C6 cycloalkyl group;
- m and n, each independently, represents 0 or an integer from 1 to 2, provided that m+n is lower than, or equal to, 2 (m+n≦2).
3 more elements
A method for treating a mammal, including humans, suffering from a disease caused by and/or associated with an altered protein kinase activity, by administering to said mammal in need thereof a therapeutically effective amount of a bicyclo-pyrazole compound of formula (I):
- wherein
- R and R1, being the same or different, are independently a hydrogen atom or an optionally substituted group selected from R′, —COR′, —COOR′, —CONHR′, —CONR′R″, —NH—C(═NH)NHR′, —C(═NH)NHR′, —SO2NHR′ or —SO2NR′R″;
- wherein R′ and R″, the same or different, are independently selected from hydrogen or optionally further substituted straight or branched C1-C6 alkyl, aryl, C3-C6 cycloalkyl or aryl C1-C6 alkyl or R′ and R″ taken together form a C4-C6 alkylene chain;
- Ra, Rb, Rc and Rd, being the same or different, are independently selected among hydrogen, optionally further substituted straight or branched C1-C6 alkyl, aryl, aryl C1-C6 alkyl or —CH2OR′ groups, wherein R′ is as above defined, or Ra and Rb and/or Rc and Rd, taken together with the carbon atom to which they are bonded, form an optionally substituted C3-C6 cycloalkyl group;
- m and n, each independently, represents 0 or an integer from 1 to 2, provided that m+n is lower than, or equal to, 2 (m+n≦2);
- or a pharmaceutically acceptable salt thereof;
- wherein said disease caused by and/or associated with an altered protein kinase activity is selected from the group consisting of Alzheimer's disease, benign prostate hyperplasia, familial adenomatosis polyposis, neuro-fibromatosis, psoriasis, pulmonary fibrosis, arthritis glomerulonephritis, post-surgical stenosis, restenosis, and cancer, wherein the cancer is selected from the group consisting of leukemia, ovary, colon, breast, lung, and pancreas.
4 more elements
Dependencies are inferred from the claim text.